These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

992 related articles for article (PubMed ID: 35474319)

  • 21. Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine.
    Arunachalam PS; Feng Y; Ashraf U; Hu M; Walls AC; Edara VV; Zarnitsyna VI; Aye PP; Golden N; Miranda MC; Green KWM; Threeton BM; Maness NJ; Beddingfield BJ; Bohm RP; Scheuermann SE; Goff K; Dufour J; Russell-Lodrigue K; Kepl E; Fiala B; Wrenn S; Ravichandran R; Ellis D; Carter L; Rogers K; Shirreff LM; Ferrell DE; Deb Adhikary NR; Fontenot J; Hammond HL; Frieman M; Grifoni A; Sette A; O'Hagan DT; Van Der Most R; Rappuoli R; Villinger F; Kleanthous H; Rappaport J; Suthar MS; Veesler D; Wang TT; King NP; Pulendran B
    Sci Transl Med; 2022 Aug; 14(658):eabq4130. PubMed ID: 35976993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice.
    Song S; Zhou B; Cheng L; Liu W; Fan Q; Ge X; Peng H; Fu YX; Ju B; Zhang Z
    Virol J; 2022 Jan; 19(1):2. PubMed ID: 34983583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine.
    Chang TY; Li CJ; Chao TL; Chang SY; Chang SC
    Appl Microbiol Biotechnol; 2024 Oct; 108(1):486. PubMed ID: 39412657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
    Muñoz-Alía MÁ; Nace RA; Balakrishnan B; Zhang L; Packiriswamy N; Singh G; Warang P; Mena I; Narjari R; Vandergaast R; Peng K-W; García-Sastre A; Schotsaert M; Russell SJ
    mBio; 2024 Feb; 15(2):e0292823. PubMed ID: 38193729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
    Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
    Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
    J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants.
    Zhong J; Liu S; Cui T; Li J; Zhu F; Zhong N; Huang W; Zhao Z; Wang Z
    Emerg Microbes Infect; 2022 Dec; 11(1):2689-2697. PubMed ID: 36197655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
    Rescigno M; Agrati C; Salvarani C; Giannarelli D; Costantini M; Mantovani A; Massafra R; Zinzani PL; Morrone A; Notari S; Matusali G; Pinter GL; Uccelli A; Ciliberto G; Baldanti F; Locatelli F; Silvestris N; Sinno V; Turola E; Lupo-Stanghellini MT; Apolone G;
    Front Immunol; 2023; 14():1104124. PubMed ID: 36776853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines.
    Luczkowiak J; Rivas G; Labiod N; Lasala F; Rolo M; Lora-Tamayo J; Mancheno-Losa M; Rial-Crestelo D; Pérez-Rivilla A; Folgueira MD; Delgado R
    J Med Virol; 2023 Jan; 95(1):e28268. PubMed ID: 36319593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
    Shen X; Hao Y; Wang S; Li D; Ren L; Zhu M; Wang S; Li J; Tang W; Fu Y; Chen R; Liu Y; Shao Y
    Vaccine; 2023 Oct; 41(45):6645-6653. PubMed ID: 37770297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine.
    Li D; Martinez DR; Schäfer A; Chen H; Barr M; Sutherland LL; Lee E; Parks R; Mielke D; Edwards W; Newman A; Bock KW; Minai M; Nagata BM; Gagne M; Douek DC; DeMarco CT; Denny TN; Oguin TH; Brown A; Rountree W; Wang Y; Mansouri K; Edwards RJ; Ferrari G; Sempowski GD; Eaton A; Tang J; Cain DW; Santra S; Pardi N; Weissman D; Tomai MA; Fox CB; Moore IN; Andersen H; Lewis MG; Golding H; Seder R; Khurana S; Baric RS; Montefiori DC; Saunders KO; Haynes BF
    Nat Commun; 2022 Oct; 13(1):6309. PubMed ID: 36274085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
    Evans JP; Zeng C; Qu P; Faraone J; Zheng YM; Carlin C; Bednash JS; Zhou T; Lozanski G; Mallampalli R; Saif LJ; Oltz EM; Mohler PJ; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2022 Aug; 30(8):1093-1102.e3. PubMed ID: 35526534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.
    Lyke KE; Atmar RL; Islas CD; Posavad CM; Szydlo D; Paul Chourdhury R; Deming ME; Eaton A; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Archer JI; Crandon S; Zemanek JA; Brown ER; Neuzil KM; Stephens DS; Post DJ; Nayak SU; Suthar MS; Roberts PC; Beigel JH; Montefiori DC;
    Cell Rep Med; 2022 Jul; 3(7):100679. PubMed ID: 35798000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
    Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.
    Ma H; Zhang X; Zheng P; Dube PH; Zeng W; Chen S; Cheng Q; Yang Y; Wu Y; Zhou J; Hu X; Xiang Y; Zhang H; Chiu S; Jin T
    Cell Res; 2022 Sep; 32(9):831-842. PubMed ID: 35906408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1.
    Balinsky CA; Jiang L; Jani V; Cheng Y; Zhang Z; Belinskaya T; Qiu Q; Long TK; Schilling MA; Jenkins SA; Corson KS; Martin NJ; Letizia AG; Hontz RD; Sun P
    Front Immunol; 2023; 14():1266829. PubMed ID: 38077368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
    He Q; An Y; Zhou X; Xie H; Tao L; Li D; Zheng A; Li L; Xu Z; Yu S; Wang R; Hu H; Liu K; Wang Q; Dai L; Xu K; Gao GF
    Med; 2024 May; 5(5):401-413.e4. PubMed ID: 38574739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.